News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
Search Query
Submit Search
News
Business
GlaxoSmithKline Names European Head Witty as New CEO
October 8, 2007
|
1 min read
Twitter
LinkedIn
Facebook
Email
Print
LONDON (Reuters) - GlaxoSmithKline (GSK.L: Quote, Profile, Research) has picked insider Andrew Witty to replace Chief Executive Jean-Pierre Garnier, resolving a long-standing succession issue at Europe's biggest drugmaker.
Twitter
LinkedIn
Facebook
Email
Print
People
Europe
MORE ON THIS TOPIC
Manufacturing
FDA’s first AI-focused cGMP warning letter signals new scrutiny for manufacturers
July 16, 2026
·
3 min read
·
John Potter
Psychedelics
Lilly makes up to $3.8B psychedelics play in AtaiBeckley takeover
July 16, 2026
·
2 min read
·
Tristan Manalac
IPO
Braveheart, Attovia, Vogenx keep IPOs ballooning with plans to compete in cardiometabolic, immuno
July 16, 2026
·
4 min read
·
Tristan Manalac
Psychedelics
J&J sees Spravato sales surge as psychedelic competitors loom
July 16, 2026
·
2 min read
·
Tristan Manalac
